• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CLEMASTINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CLEMASTINE chembl:CHEMBL1626 Approved

    Alternate Names:

    CLEMASTINE
    HS-592
    TAVEGIL®
    MECLASTIN
    CLEMASTINUM
    (+)-(2R)-2-(2-(((R)-P-CHLORO-ALPHA-METHYL-ALPHA-PHENYLBENZYL)OXY)ETHYL)-1-METHYLPYRROLIDINE
    TAVIST®
    (+)-(2R)-2-[2-[[(R)-P-CHLORO-Α-METHYL-Α-PHENYLBENZYL]OXY]ETHYL]-1-METHYLPYRROLIDINE
    CLEMASTINA
    (+)-(2R)-2-(2-(((R)-P-CHLORO-Α-METHYL-Α-PHENYLBENZYL)OXY)ETHYL)-1-METHYLPYRROLIDINE
    (+)-(2R)-2-[2-[[(R)-P-CHLORO-ALPHA-METHYL-ALPHA-PHENYLBENZYL]OXY]ETHYL]-1-METHYLPYRROLIDINE
    drugbank:00283
    chemidplus:15686-51-8
    pubchem.compound:26987
    chembl:CHEMBL1626
    rxcui:2578

    Drug Info:

    Year of Approval 1977
    Drug Class anti-allergic agents
    FDA Approval 1977
    Drug Class small molecule
    Drug Indications Anti-Allergic Agents
    (1 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Dorsch et al., 1984, Sequential histamine inhalations cause increased bronchial histamine reactivity in guinea pigs: role of platelets, thromboxanes and prostacyclin., Naunyn Schmiedebergs Arch. Pharmacol.
    Schran et al., 1996, The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations., J Clin Pharmacol
    Taniguchi et al., 1991, Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils., J. Pharmacobio-dyn.
    Taniguchi et al., 1987, [Effects of antiallergic agents on polymorphonuclear leukocytes. The inhibition of arachidonic acid release and superoxide production]., Nippon Yakurigaku Zasshi
    Oishi et al., 1994, Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain., Naunyn Schmiedebergs Arch. Pharmacol.
    Hallberg et al., 1984, Demonstration of histamine receptors on human platelets by flow cytometry., Scand J Haematol
    Thomson et al., 1980, Effect of inhaled H1 and H2 receptor antagonist in normal and asthmatic subjects., Thorax
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Hayashi et al., 1976, Atrial T (Ta) loop in dogs with or without atrial injury., Am. Heart J.
    Thomas et al., 1985, The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin., Br J Clin Pharmacol
  • CLEMASTINE   HRH1

    Interaction Score: 0.8

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    6387510 8930778 1678430 2890562 7513381 6701456 6449094 11752352 1266718 4074605


    Sources:
    TdgClinicalTrial TEND TTD

  • CLEMASTINE   THPO

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CLEMASTINE   CYP2C9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CLEMASTINE   CYP1A2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CLEMASTINE   CYP2D6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CLEMASTINE   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CLEMASTINE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CLEMASTINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: CLEMASTINE

    • Version: 01-August-2011

    Alternate Names:
    CLEMASTINE Primary Drug Name

    Drug Info:
    Drug Class anti-allergic agents
    Year of Approval 1977

    Publications:

  • TdgClinicalTrial: CLEMASTINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Anti-Allergic Agents
    Drug Class small molecule
    FDA Approval 1977

    Publications:

  • DTC: CLEMASTINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1626 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • TTD: Clemastine

    • Version: 2020.06.01

    Alternate Names:
    D0C5XC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1626

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21